ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Malignancy"

  • 2021 American Transplant Congress

    Prostate Cancer Mortality is Not Worse Among Kidney Transplant Recipients Compared to Dialysis Patients

    N. Sarabu1, W. Dong2, S. M. Koroukian2

    1University Hospital Cleveland Medical Center, Cleveland, OH, 2Case Western Reserve University, Cleveland, OH

    *Purpose: Recent recommendations from expert panel of American Society of Transplantation (AST) state that most patients with prostate cancer (PCa) do not need to wait…
  • 2021 American Transplant Congress

    Development of De-novo Malignancies After Kidney and/or Pancreas Transplantation in Diabetic Patients

    A. Gruessner, S. Saggi, J. Renz, R. Gruessner

    SUNY Downstate Medical Center, Brooklyn, NY

    *Purpose: Transplantation of a kidney (KTA), pancreas (PTA), or a simultaneous pancreas-kidney (SPK) in a patient with end-stage organ failure is a lifesaving treatment. Patient…
  • 2021 American Transplant Congress

    Posttransplant Malignancy in HIV+ Kidney Transplant Recipients

    D. Sawinski1, R. Fitzsimmons1, J. Locke2, J. Trofe-Clark1, B. Shelton2, P. Reese1, E. Blumberg1

    1Hospital of the University of Pennsylvania, Philadelphia, PA, 2University of Alabama at Birmingham, Birmingham, AL

    *Purpose: Kidney transplant recipients and people living with HIV are both at increased risk for malignancy, including cancers that are virally-mediated. Despite the recognition of…
  • 2021 American Transplant Congress

    Associations of Mammalian Target of Rapamycin Inhibitors with Post-Transplant Malignancies and All-Cause Mortality: Cause-Specific Competing Risks and Composite Outcomes Analyses

    A. H. Santos1, E. Bueno1, M. A. Leghrouz1, W. Xuerong2

    1University of Florida, Gainesville, FL, 2University of Rhode Island, Kingston, RI

    *Purpose: We investigated the outcomes of malignancies and mortality associated with mammalian target of rapamycin inhibitor (MTORI) regimens in adult kidney transplant (KT) recipients (KTRs).*Methods:…
  • 2021 American Transplant Congress

    Long Term Survival After Liver Transplantation for Advanced, Unresectable Intrahepatic Cholangiocarcinoma

    R. R. McMillan1, S. Kodali1, M. Javle2, A. Saharia1, C. M. Mobley1, M. J. Hobeika1, A. Shetty1, D. W. Victor1, R. McFadden1, M. Abdelrahim1, K. Heyne1, A. O. Gaber1, R. M. Ghobrial1

    1Houston Methodist Hospital, Houston, TX, 2MD Anderson Cancer Center, Houston, TX

    *Purpose: Intrahepatic cholangiocarcinoma (ICCA) has traditionally been considered a contraindication to liver transplantation (LT). We previously reported a case series of six patients with large,…
  • 2021 American Transplant Congress

    Treg Lymphotoxin Engages Lymphotoxin Receptor on Cancer and Endothelial Cells to Promote Cancer Metastatic Migration: Mechanisms for Treg-Cancer Interactions

    W. Piao, R. Oakes, C. Paluskievicz, J. Christopher, J. Bromberg

    U Maryland, Baltimore, MD

    *Purpose: Treg immune suppression which is critical for transplant graft survival may also enhance tumor growth and metastases. Treg lymphotoxin (LTα1β2) may directly engage the…
  • 2021 American Transplant Congress

    Cancer Among Kidney Transplant Recipients More Than 20 Years After Transplantation: PTLD Remains the Most Common Cancer Type Even in the Very Long-Term

    T. Schachtner, J. Fuhrmann, T. Mueller

    Nephrology, University Hospital Zurich, Zurich, Switzerland

    *Purpose: Due to an improved patient and kidney allograft survival, cancer is increasingly recognized as the major cause of death after kidney transplantation. Cancer risk…
  • 2021 American Transplant Congress

    Impact of Donation After Circulatory Death Donor Allografts on Outcomes Following Liver Transplantation for Cholangiocarcinoma

    S. Kumar1, S. Lin2, J. D. Schold2

    1Digestive Disease Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates, 2Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH

    *Purpose: Improvements in the management of extra-hepatic cholangiocarcinoma (CCA) resulted in allocation of a standardized model for end-stage liver disease (MELD) exception score for liver…
  • 2021 American Transplant Congress

    Excellent Pathological Response with Gemcitabine-based Protocol in Patient with Hilar Cholangiocarcinoma

    A. Saharia1, R. McMillan1, S. Kodali1, M. Javley2, C. M. Mobley1, M. J. Hobeika1, A. Shetty1, D. W. Victor1, R. McFadden1, M. Abdelrahim1, K. Heyne1, A. O. Gaber1, R. M. Ghobrial1

    1Houston Methodist Hospital, Houston, TX, 2MD Anderson Cancer Center, Houston, TX

    *Purpose: The standard treatment for hilar cholangiocarcinoma is using 5FU along with brachytherapy and external beam radiation. The downside of this regimen is the uncertain…
  • 2020 American Transplant Congress

    Multimodal Strategy for Hepatocellular Carcinoma in the Elderly: To Transplant or Not to Transplant

    M. Najjar1, O. Perez1, J. Zou1, S. Sun1, K. Bruestle1, P. Jiang1, E. Verna1, E. Zheng1, Y. Saenger1, A. Mathur1, A. Griesemer1, B. Samstein2, T. Kato1, K. Halazun2, J. Emond1

    1Columbia University Irving Medical Center, New York, NY, 2Weill Cornell Medicine, New York, NY

    *Purpose: Liver transplantation LT for HCC is curative but entails increased risk and is limited by organ scarcity. Alternative approaches such as locoregional therapy (LRT)…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 20
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences